A 600-patient randomized trial is a substantial bet for a company of ORIC Pharmaceuticals’ size, and the structure of the Himalayas-1 agreement reveals exactly how the company is managing that risk. Bayer supplies darolutamide at no cost under a clinical collaboration, but retains no license, option, or other rights to rinzimetostat. ORIC sponsors the trial and keeps full global development and commercial rights. That is an unusually clean arrangement: Bayer gets real-world combination data for a drug it already sells, and ORIC gets a funded supply chain for its backbone comparator without surrendering any future upside.
The Himalayas-1 trial targets patients with mCRPC previously treated with abiraterone, a population that has progressed through one standard hormonal pathway and faces genuinely limited options. The trial will randomize approximately 600 patients 1:1 across more than 250 sites in 25 countries, comparing 400 mg once-daily rinzimetostat plus darolutamide against physician’s choice of an androgen receptor inhibitor or docetaxel. The primary endpoint is radiographic progression-free survival, with overall survival as the key secondary endpoint. That rPFS-first design is consistent with current regulatory expectations in mCRPC and gives ORIC a realistic path to an accelerated or standard approval without requiring a survival readout as the initial hurdle. The 400 mg once-daily dose was selected as the recommended Phase 3 dose after earlier combination work with darolutamide, and the protocol was finalized following End-of-Phase 1 interactions with FDA and other global health authorities.
The mechanism here matters. Rinzimetostat is an allosteric inhibitor of the polycomb repressive complex 2 via the EED subunit, a distinct approach from androgen receptor targeting. The hypothesis is that PRC2 inhibition addresses an epigenetic resistance mechanism that allows prostate cancer cells to survive AR pathway suppression. Pairing it with darolutamide, which holds FDA approvals in non-metastatic castration-resistant and metastatic castration-sensitive prostate cancer, gives the combination clinical credibility and a well-characterized safety reference point for regulators and investigators.
The number to track from here is not enrollment pace but rPFS event accumulation. At 600 patients across 25 countries, enrollment can move reasonably fast; the trial’s timeline will ultimately compress or extend depending on how quickly the trial reaches the event threshold needed to trigger the primary analysis. An interim overall survival signal at that readout, even if immature, will carry outsized weight with both regulators and potential acquirers.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
